Study Title
A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).
Study Details
Description:
The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with somatostatin receptor (SSTR)-positive tumors.
Sponsor:
ITM Solucin GmbH
Contacts:
Serhii Melnyk, PhDinfo-solucin@itm-radiopharma.com
Shahanaz Rahmaninfo-solucin@itm-radiopharma.com
089 32989866000
Government Study Link:
NCT06441331 - Click here to see study onClinicalTrials.gov